Tags: liver | efruxifermin | akero therapeutics | pre-cirrhotic nonalcoholic steatohepatitis | nash

Akero Therapeutics Liver Drug Found Effective in Trial

entry in medical book for Fatty Liver Disease, pills, stethoscope
(Dreamstime)

Tuesday, 13 September 2022 09:13 AM EDT

Akero Therapeutics Inc said on Tuesday its lead experimental drug met the main goal for treatment of a type of fatty liver disease, sending the company's shares soaring more than 60% in premarket trading.

Both doses of the drug, efruxifermin, being studied in a mid-stage trial showed improvement in patients with pre-cirrhotic nonalcoholic steatohepatitis (NASH) by week 24 compared with the placebo arm, according to the company.

It is estimated that about 5% of adults in the United States have NASH, according to the American Liver Foundation, but there is no approved treatment for the ailment.

This makes it a lucrative opportunity for drugmakers, with Pfizer Inc as well as smaller companies such as Madrigal Pharmaceuticals Inc and Intercept Pharmaceuticals Inc developing treatments.

About 40% of the patients in each of the 50 mg and 28 mg dosage groups showed at least a one-stage improvement in liver scarring by week 24 compared with 20% for the placebo arm, Akero said, adding that the study also met its secondary endpoints. 

© 2025 Thomson/Reuters. All rights reserved.


Health-News
Akero Therapeutics Inc said on Tuesday its lead experimental drug met the main goal for treatment of a type of fatty liver disease, sending the company's shares soaring more than 60% in premarket trading. Both doses of the drug, efruxifermin, being studied in a mid-stage...
liver, efruxifermin, akero therapeutics, pre-cirrhotic nonalcoholic steatohepatitis, nash
169
2022-13-13
Tuesday, 13 September 2022 09:13 AM
Newsmax Media, Inc.

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

(Optional for Local News)
Privacy: We never share your email address.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
Find Your Condition
Newsmax2 Live
 
On Now:12:00a ET • Nuclear Now
Coming Up:2:30a ET • Jesus in Jerusalem: His Story
Get Newsmax Text Alerts

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© 2025 Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved